A Shortage of Neurologists – We Must Act Now
A Report From the AAN 2019 Transforming Leaders Program
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 10, 2020
- Accepted in final form March 4, 2021
- First Published April 30, 2021.
Article Versions
- Previous version (April 30, 2021 - 12:56).
- You are viewing the most recent version of this article.
Author Disclosures
- Jennifer J. Majersik, MD, MS,
- Aiesha Ahmed, MD, MBA,
- I-Hweii A. Chen, MD, PhD,
- Holly Shill, MD,
- Gregory P. Hanes, MD,
- Victoria S. Pelak, MD,
- Jennifer L. Hopp, MD,
- Antonio Omuro, MD,
- Benzi Kluger, MD, MS and
- Thabele Leslie-Mazwi, MD
- Jennifer J. Majersik, MD, MS,
NONE
NONE
NONE
(1) Neurology, Editorial Board Member, 2015-present (2) Stroke, Associate Editor, 2020-present (3) UpToDate, Reviewer, 2018-present
NONE
NONE
NONE
(1) Commercial entity, Foldax, Inc (2019-20)
NONE
NONE
NONE
NONE
(1) NIH/NINDS, 1U24NS107228 - UT StrokeNet, Principal Investigator, 2018-23 (2) NIH/NINDS, 1U24NS107156 - UR NEXT, Mentor, 2018-23 (3) NIH/NICHD, 1R03HD091432 - Co-Investigator, 2017-19
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aiesha Ahmed, MD, MBA,
Genzyme
NONE
AAN
NONE
NONE
NONE
NONE
NONE
Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- I-Hweii A. Chen, MD, PhD,
served on Biogen ad-hoc advisory board (2019)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
receive research funding support from NEALS (2019-2020) and UCB (2019)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Holly Shill, MD,
US World Meds
NONE
NONE
NONE
NONE
NONE
NONE
Mitsubishi Tanabe Pharma America, Acadia Pharmaceuticals, Biogen, Kyowa Kirin, Jazz Pharmaceuticals, Acorda Therapeutics
NONE
NONE
NONE
Dr. Shill has research support from Impax Laboratories, US World Meds, Sunovion, Biogen, Intec Pharma, Cala Health
NINDS/NIH. NN110: A Dose Selection Trial of Light Therapy for Impaired Sleep in ParkinsonÂs Disease. Oct. 2020- present. Role: Local PI. NINDS/NIH. Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). 9/2018-present. Role: Co-PI. 10% FTE. 1U01NS090259-01A1. NIH/Parkinson Study Group. A randomized, double-blind, placebo-controlled trial of urate-elevating inosine treatment to slow clinical decline in early ParkinsonÂs disease. SURE-PD. 10/2016- 12/2019. Role: Local PI. 1% FTE
NONE
Michael J Fox Foundation for Parkinson Research Barrow Neurological Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Gregory P. Hanes, MD,
NONE
NONE
1. AbbVie, Inc., honoraria for speaking engagement 2. Catalyst Pharmaceuticals, Inc., honoraria for speaking engagement 3. Allergan PLC, honoraria for speaking engagement
NONE
NONE
NONE
NONE
1. Allergan, PLC 2. AbbVie, Inc. 3. Maglio, Christoher, and Toale, PA
1. Allergan, PLC. 2. AbbVie, Inc. 3. Catalyst Pharmaceuticals, Inc.
NONE
NONE
1. Allergan, PLC. 2. AbbVie, Inc.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Victoria S. Pelak, MD,
NONE
NONE
NONE
1. Frontiers Neurology: Dementia, (Review Editor), (2018- 2019) 2. Neuro-ophthalmology Virtual Education Library, (Editorial Board), (2018-Present) 3. NOVEL Neuro-ophthalmology Examination Techniques, (Section Editor), (2018-present) 4. Frontiers Neurology: Neuro-ophthalmology (Associate Editor), (2018-Present) 5. Journal of Neuro-ophthalmology, (Editorial Board), (2019-Present) 6. Scientific Reports: Nature, (Editorial Board), (2020- Present) 7. Brain & Life Magazine, (Editorial Board), (2020- Present) 8. StatPearls, (Editor-in-Chief Behavioral Neurology and Neuropsychiatry Section), (2020-Present)
NONE
UpToDate, Inc, Royalties for Articles recvd semi-annually for these publications in UpToDate. 1. Pelak VS, Quan D. Ocular Myasthenia Gravis. In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA. 2006. 2. Pelak VS. Visual Hallucinations I and II. In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2009. 3. Pelak VS. Release Visual Hallucinations (Charles Bonnet Syndrome). In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2009.
NONE
NONE
NONE
NONE
NONE
NONE
NIH, 1R01AG058772-01A1, Co-Investigator, 5 years, NIA
NONE
1. North American Neuro-ophthalmology Society 2. Alzheimer's Association 3. Visual Snow Initiative
NONE
NONE
NONE
NONE
NONE
1) expert witness testimony and deposition - private lawyers 2) treating physician deposition - private lawyers 3) expert for National Vaccine Injury Compensation Program, Health and Human Services, Health Resources & Services Administration
- Jennifer L. Hopp, MD,
NONE
NONE
NONE
NONE
NONE
(1) Driving restrictions for patients with seizures and epilepsy, UpToDate electronic medical journal, 2007- present
NONE
NONE
NONE
NONE
NONE
NONE
(1) NINDS 1 UO1 NS08803401, Established Status Epilepticus Treatment Trial (ESETT), Site-PI, Co- Investigator, 2015-2020 (2) 1 U10 NS058932-01 NIH NINDS Neurological Emergencies Treatment Trials (NETT) Network Clinical/Site Hub, PI Maryland Consortium NETT Network Hub, 2017-2020 (3) MII TA Grant 20180828 TEDCO, EpiWatch: A Mobile Health Application for Epilepsy Management, Role: Site PI, Co-Investigator, 2018-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)GEROLAMO McNULTY DIVIS & LEWBART, A PROFESSIONAL CORPORATION ATTORNEYS AT LAW, Expert witness testimony, 2019-present (2) GOODELL, DEVRIES, LEECH & DANN, LLP, Expert witness testimony, 2020-present
- Antonio Omuro, MD,
(1) Ono (2) Merck (3) Kiyatec
NONE
NONE
Current Opinion in Neurology, associate editor for Neoplasm edition, 2019
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH, 5P30CA016359-40, Chair, protocol review committee
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Benzi Kluger, MD, MS and
NONE
NONE
1) Davis Phinney Foundation - Speaker Honoraria 2) Parkinson's Association of the Rockies - Speaker Honoraria 3) Movement Disorders Society - Speaker Honoraria
1) Frontiers in Movement Disorders, Editorial Board 2) Annals of Palliative Medicine, Editorial Board 3) Palliative Medicine Reports, Editorial Board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) National Institutes of Health/NIA, PI, NIH, K02AG062745, 2020-2025 K02 NS080885-01A1 2) NIH/NINR, PI, R01NR016037, 2016-2021
NONE
1) Patient Centered Outcomes Research Institute
NONE
NONE
NONE
NONE
NONE
NONE
- Thabele Leslie-Mazwi, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology, Division of Vascular Neurology (J.J.M.), University of Utah, Salt Lake City; Departments of Neurology and Medicine (A.A.), Penn State Health, Hershey, PA; Department of Neurology, Division of Neuromuscular Medicine (I-H.A.C.), Medical University of South Carolina, Charleston; Barrow Neurological Institute (H.S.), University of Arizona College of Medicine–Phoenix; Sarasota Memorial Hospital (G.P.H.), FL; Departments of Neurology and Ophthalmology (V.S.P.), University of Colorado School of Medicine, Aurora; Department of Neurology (J.L.H.), University of Maryland School of Medicine, Baltimore; Department of Neurology (A.O.), Yale School of Medicine, New Haven, CT; Departments of Neurology and Medicine (B.K.), University of Rochester Medical Center, NY; and Departments of Neurosurgery and Neurology (T.L.-M.), Massachusetts General Hospital, Boston.
- Correspondence
Dr. Majersik jennifer.majersik{at}hsc.utah.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan
Related Articles
- No related articles found.